8.38
price down icon1.18%   -0.10
after-market Dopo l'orario di chiusura: 8.32 -0.06 -0.72%
loading
Precedente Chiudi:
$8.48
Aprire:
$8.4
Volume 24 ore:
1.11M
Relative Volume:
0.52
Capitalizzazione di mercato:
$3.08B
Reddito:
$9.47B
Utile/perdita netta:
$-178.00M
Rapporto P/E:
-3.1742
EPS:
-2.64
Flusso di cassa netto:
$1.01B
1 W Prestazione:
-10.37%
1M Prestazione:
+2.70%
6M Prestazione:
+23.78%
1 anno Prestazione:
+21.45%
Intervallo 1D:
Value
$8.3619
$8.51
Intervallo di 1 settimana:
Value
$8.3619
$9.31
Portata 52W:
Value
$3.96
$11.46

Bausch Health Companies Inc Stock (BHC) Company Profile

Name
Nome
Bausch Health Companies Inc
Name
Telefono
514-744-6792
Name
Indirizzo
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Name
Dipendente
20,270
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
BHC's Discussions on Twitter

Confronta BHC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
BHC 8.38 3.08B 9.47B -178.00M 1.01B -2.64
ZTS 176.42 79.51B 9.15B 2.43B 2.31B 4.92
TAK 13.53 42.89B 30.27B 1.93B 3.45B 0.444
HLN 9.43 42.57B 14.26B 1.55B 0 0.3327
TEVA 16.49 18.51B 16.77B -959.00M 1.37B -2.00
VTRS 13.00 15.37B 15.24B -646.50M 1.88B 1.53

Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-09-20 Aggiornamento Jefferies Hold → Buy
2023-06-16 Downgrade TD Cowen Outperform → Market Perform
2022-07-29 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-07-29 Downgrade Truist Buy → Hold
2022-07-28 Downgrade JP Morgan Overweight → Neutral
2022-06-13 Ripresa JP Morgan Overweight
2021-03-24 Downgrade BofA Securities Neutral → Underperform
2021-02-17 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2021-01-22 Downgrade Piper Sandler Overweight → Neutral
2020-09-17 Aggiornamento BofA Securities Underperform → Neutral
2020-08-24 Reiterato H.C. Wainwright Buy
2020-06-17 Reiterato H.C. Wainwright Buy
2020-04-24 Iniziato Citigroup Buy
2020-04-02 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-01-29 Downgrade Wolfe Research Outperform → Peer Perform
2020-01-22 Aggiornamento Wells Fargo Underweight → Equal Weight
2019-12-12 Aggiornamento JP Morgan Neutral → Overweight
2019-12-02 Iniziato Goldman Neutral
2019-10-25 Iniziato Cowen Outperform
2019-09-12 Iniziato Guggenheim Buy
2019-08-15 Aggiornamento TD Securities Hold → Buy
2019-07-19 Iniziato Wolfe Research Outperform
2019-06-11 Ripresa Barclays Overweight
2019-05-13 Aggiornamento JP Morgan Underweight → Neutral
2019-03-20 Iniziato SunTrust Buy
2019-01-02 Aggiornamento Piper Jaffray Neutral → Overweight
2018-11-05 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2018-09-13 Aggiornamento Piper Jaffray Underweight → Neutral
Mostra tutto

Bausch Health Companies Inc Borsa (BHC) Ultime notizie

pulisher
09:50 AM

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug - Marketscreener.com

09:50 AM
pulisher
09:42 AM

Herpes Zoster Oticus Market: Company Profiles, Segment Sizes, - openPR

09:42 AM
pulisher
08:02 AM

Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis - AccessWire

08:02 AM
pulisher
08:00 AM

Bausch Health's Triple-Action Acne Treatment CABTREO Gains Key Canadian Approvals | BHC Stock News - StockTitan

08:00 AM
pulisher
Nov 14, 2024

Common Warts Treatment Market Trade Analysis and Statistical - openPR

Nov 14, 2024
pulisher
Nov 14, 2024

Underactive Bladder Treatment Market Expected to Reach Huge - openPR

Nov 14, 2024
pulisher
Nov 13, 2024

Genital Herpes Treatment Market Global Share, Trends, Business - openPR

Nov 13, 2024
pulisher
Nov 13, 2024

Varicella Zoster (HHV-3) Infections Treatment Market Share, - openPR

Nov 13, 2024
pulisher
Nov 13, 2024

Vitrectomy Devices Market is expected to reach US$ 2121.3 - openPR

Nov 13, 2024
pulisher
Nov 12, 2024

22q11.2 Deletion Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas - The Globe and Mail

Nov 12, 2024
pulisher
Nov 12, 2024

Actinic Keratosis Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyze | Bausch Health Companies, Sandoz Pharma, Athenex, Almirall, Vidac Pharma, G&E Herbal Biotech - Barchart

Nov 12, 2024
pulisher
Nov 11, 2024

Periodontal Therapeutics Market to Grow at a Promising CAGR - openPR

Nov 11, 2024
pulisher
Nov 07, 2024

Myopia and Presbyopia Treatment Market to Grow by USD 9.76 Billion from 2024-2028, as Rising Prevalence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve

Nov 07, 2024
pulisher
Nov 07, 2024

Are Medical Stocks Lagging Bausch Health (BHC) This Year? - MSN

Nov 07, 2024
pulisher
Nov 06, 2024

Body Contouring Treatments Market to Hit USD 2.58 Billion by 2029 with 10.0% CAGR | MarketsandMarkets™ - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Eye Health Supplements Market Trends and Growth Projections - openPR

Nov 06, 2024
pulisher
Nov 05, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve

Nov 05, 2024
pulisher
Nov 05, 2024

189,000 Shares in Bausch Health Companies Inc. (NYSE:BHC) Bought by Intact Investment Management Inc. - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

Bausch Health Companies' SWOT analysis: debt woes cloud strong Q3 stock performance - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Nov 04, 2024
pulisher
Nov 02, 2024

Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Bausch Health secures $400 million loan amendment - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Bausch Health secures $400 million loan amendment By Investing.com - Investing.com UK

Nov 01, 2024
pulisher
Nov 01, 2024

Bausch Health Companies (NYSE:BHC) Price Target Raised to $11.00 at Royal Bank of Canada - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Bausch Health Companies Inc. (NYSE:BHC) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Bausch Health Companies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Nov 01, 2024
pulisher
Nov 01, 2024

Bausch Health stock outlook lifted as RBC cites robust Q3 growth and tax benefits - Investing.com

Nov 01, 2024
pulisher
Oct 31, 2024

Traders Purchase High Volume of Bausch Health Companies Put Options (NYSE:BHC) - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Toronto Stocks Drop, Canada's GDP Flat in August; Bausch Health Rises on 3Q Beat - Marketscreener.com

Oct 31, 2024
pulisher
Oct 31, 2024

Bausch Health Shares Rise on FY Outlook Upgrade, 3Q Beat - MarketWatch

Oct 31, 2024
pulisher
Oct 31, 2024

Bausch Health Companies (NYSE:BHC) Trading 8.7% Higher on Better-Than-Expected Earnings - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Bausch Health Companies (TSE:BHC) Stock Price Up 8.4% Following Earnings Beat - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

BHCBausch Health Companies Inc. Latest Stock News & Market Updates - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Bausch: Q3 Earnings Snapshot - Houston Chronicle

Oct 31, 2024
pulisher
Oct 31, 2024

Bausch Health Reports Growth Amid Improved Financials - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Compared to Estimates, Bausch (BHC) Q3 Earnings: A Look at Key Metrics - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Bausch Health (BHC) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Bausch Health Companies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024
pulisher
Oct 30, 2024

Bausch Health Announces Third Quarter 2024 Results - AccessWire

Oct 30, 2024
pulisher
Oct 30, 2024

Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR

Oct 30, 2024
pulisher
Oct 29, 2024

Bausch Health Companies Q3 2024 Earnings Preview - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

Onychomycosis Treatment Market Size, Industry Analysis, - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

Actinic Keratosis Treatment Market Expected to Reach Huge - openPR

Oct 29, 2024
pulisher
Oct 29, 2024

Canada Aesthetic Devices Market Size, Share, Industry Growth, - openPR

Oct 29, 2024
pulisher
Oct 28, 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking - Marketscreener.com

Oct 28, 2024
pulisher
Oct 27, 2024

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence - StockTitan

Oct 27, 2024
pulisher
Oct 26, 2024

TD COWEN Downgrades Bausch Health Companies (BHC) - MSN

Oct 26, 2024
pulisher
Oct 26, 2024

Deal Dispatch: TKO Buys Bull Riding, Radford Motors Is BankruptApollo Global Management (NYSE:APO), Bausch Health Companies (NYSE:BHC) - Benzinga

Oct 26, 2024
pulisher
Oct 25, 2024

Bausch Health Companies (NYSE:BHC) Lifted to "Buy" at StockNews.com - MarketBeat

Oct 25, 2024
pulisher
Oct 24, 2024

FY2024 EPS Estimates for TSE:BHC Lifted by Zacks Research - MarketBeat

Oct 24, 2024

Bausch Health Companies Inc Azioni (BHC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$76.22
price down icon 0.79%
$13.45
price down icon 3.79%
$82.47
price down icon 1.14%
$58.78
price down icon 0.54%
$117.62
price up icon 0.15%
$13.00
price up icon 1.33%
Capitalizzazione:     |  Volume (24 ore):